Table 1)a Solicited local and systemic adverse reactions collected for participants in a safety subset (N=6,736)b Pain – Grade 3: any use of prescription pain reliever or prevented daily activityc Erythema and Swelling – Grade 3: >100mmNote: No grade 4 local reactions were reported.Systemic reactions were reported at higher rates by vaccine recipients than placebo recipients.
The frequency of systemic reactions was higher in participants aged 18-59 years than participants ≥60 years (61.5% vs 45.3%).
For both age groups, fatigue and headache were the most commonly reported systemic reactions. Fever was more common in participants 18-59 years (12.8%) compared to those ≥60 years (3.1%).